Merck Seeks To Boost $200M Award In Gilead Drug IP Case
On the heels of last week's jury verdict that Gilead Sciences Inc. must pay Merck & Co. Inc. $200 million in a patent case over hepatitis C drugs, Merck asked a...To view the full article, register now.
Already a subscriber? Click here to view full article